Loading...
Market
Which disease will PepFlow AI Model impact most by 2025?
1
Resolution / Starting Odds
Cancer • 33%
Neurodegenerative diseases • 33%
Cardiovascular diseases • 33%
Published research papers, University of Toronto announcements
Story
University of Toronto's PepFlow AI Model Surpasses AlphaFold 2 in Peptide Prediction, Boosting Supercomputing
Jun 29, 2024, 10:01 AM
Researchers at the University of Toronto's Donnelly Centre have developed a new AI model, PepFlow, which surpasses the performance of Google DeepMind's AlphaFold 2 in predicting peptide structures. This breakthrough in AI and supercomputing is expected to accelerate drug discovery and provide deeper insights into disease mechanisms. The development of PepFlow highlights the significant advancements in AI technology, particularly in the field of protein structure prediction, which has been a critical area of study for structural biologists for nearly a century.
View original story
Similar markets
Diabetes • 25%
Cancer • 25%
Cardiovascular diseases • 25%
Other • 25%
Cardiovascular disease • 25%
Diabetes • 25%
Cancer • 25%
Other • 25%
Cancer • 25%
Cardiovascular disease • 25%
Neurological disorder • 25%
Other • 25%
Tuberculosis • 25%
COVID-19 • 25%
Influenza • 25%
Other • 25%
Parkinson's Disease • 25%
Heart Disease • 25%
Spinal Cord Injury • 25%
Other • 25%
Autoimmune diseases • 25%
Infectious diseases • 25%
Cancer • 25%
Other • 25%
ChatGPT-4 • 25%
Google's Med-PaLM • 25%
IBM Watson Health • 25%
Other • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsening outcomes • 25%
Yes • 50%
No • 50%
Pneumonia • 25%
Asthma • 25%
Chronic Obstructive Pulmonary Disease (COPD) • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
None • 25%